Intranasal H5 Vaccine Sparks Broad Immune Response Across Diverse Avian Flu Strains
November 13, 2025
-
2 min
7 Key Takeaways
-
1
Study on a new intranasal H5 influenza vaccine conducted.
-
2
Involved 40 healthy adults aged 18-4
-
3
Regimen included recombinant H5 vaccine and nanoemulsion adjuvant.
-
4
Priming via the mucosal route activates local immunity.
-
5
Mild side effects observed, no serious adverse events.
-
6
Significant mucosal antibody production noted.
-
7
Findings suggest potential for further trials and development.
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health have initiated a study on a new intranasal vaccine targeting the H5 subtype of avian influenza. This recombinant H5 hemagglutinin vaccine, combined with a nanoemulsion adjuvant, was tested for safety and immunogenicity in 40 healthy adults. The regimen was well tolerated, showing mild side effects, but it successfully activated mucosal immunity, indicating potential for broader protection and enhanced pandemic preparedness through mucosal routes.
Listen Tab content
